Roles of the fibroblast growth factor signal transduction system in tissue injury repair

Abstract

Following injury, tissue autonomously initiates a complex repair process, resulting in either partial recovery or regeneration of tissue architecture and function in most organisms. Both the repair and regeneration processes are highly coordinated by a hierarchy of interplay among signal transduction pathways initiated by different growth factors, cytokines and other signaling molecules under normal conditions. However, under chronic traumatic or pathological conditions, the reparative or regenerative process of most tissues in different organs can lose control to different extents, leading to random, incomplete or even flawed cell and tissue reconstitution and thus often partial restoration of the original structure and function, accompanied by the development of fibrosis, scarring or even pathogenesis that could cause organ failure and death of the organism. Ample evidence suggests that the various combinatorial fibroblast growth factor (FGF) and receptor signal transduction systems play prominent roles in injury repair and the remodeling of adult tissues in addition to embryonic development and regulation of metabolic homeostasis. In this review, we attempt to provide a brief update on our current understanding of the roles, the underlying mechanisms and clinical application of FGFs in tissue injury repair.

Keywords

Tissue injury / Repair / Regeneration / Cell growth / Fibroblast growth factor / Signal transduction

References

[1] Baddour JA, Sousounis K, Tsonis PA. Organ repair and regeneration: an overview. Birth Defects Res C Embryo Today. 2012; 96: 1-29.

[2] Edgar L, Pu T, Porter B, Aziz JM, la Pointe C, Asthana A, et al. Regenerative medicine, organ bioengineering and transplantation. Br J Surg. 2020; 107: 793-800.

[3] Eming SA, Martin P, Tomic-Canic M. Wound repair and regeneration: mechanisms, signaling, and translation. Sci Transl Med. 2014; 6: 265sr6. doi: 10.1126/scitranslmed.3009337.

[4] Eming S, Wynn T, Martin P. Inflammation and metabolism in tissue repair and regeneration. Science. 2017; 356: 1026-30.

[5] Tanner Y, Grose RP. Dysregulated FGF signalling in neoplastic disorders. Semin Cell Dev Biol. 2016; 53: 126-35.

[6] Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001; 2: REVIEWS3005. doi: 10.1186/gb-2001-2-3-reviews3005.

[7] Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet. 2004; 20: 563-9.

[8] Birnbaum D, Popovici C, Roubin R. A pair as a minimum: the two fibroblast growth factors of the nematode Caenorhabditis elegans. Dev Dyn. 2005; 232: 247-55.

[9] Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009; 8: 235-53.

[10] Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015; 4: 215-66.

[11] Krejci P, Prochazkova J, Bryja V, Kozubik A, Wilcox WR.Molecular pathology of the fibroblast growth factor family. Hum Mutat. 2009; 30: 1245-55.

[12] Li X. The FGF metabolic axis. Front Med. 2019; 13: 511-30.

[13] Luo Y, Ye S, Li X, Lu W. Emerging structure-function paradigm of endocrine FGFs in metabolic diseases. Trends Pharmacol Sci. 2019; 40: 142-53.

[14] Goldfarb M. Fibroblast growth factor homologous factors: evolution, structure, and function. Cytokine Growth Factor Rev. 2005; 16: 215-20.

[15] Belov AA, Mohammadi M. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect Biol. 2013; 5: a015958.

[16] Fernandes-Freitas I, Owen BM. Metabolic roles of endocrine fibroblast growth factors. Curr Opin Pharmacol. 2015; 25: 30-5.

[17] Goetz R, Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol. 2013; 14: 166-80.

[18] Regeenes R, Silva PN, Chang HH, Arany EJ, Shukalyuk AI, Audet J, et al. Fibroblast growth factor receptor 5 (FGFR5) is a co-receptor for FGFR1 that is up-regulated in beta-cells by cytokine-induced inflammation. J Biol Chem. 2018; 293: 17218-28.

[19] McKeehan WL, Wang F, Kan M. The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol. 1998; 59: 135-76.

[20] Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10: 116-29.

[21] Müller AK, Meyer M, Werner S. The roles of receptor tyrosine kinases and their ligands in the wound repair process. Semin Cell Dev Biol. 2012; 23: 963-70.

[22] Kulebyakin KY, Nimiritsky PP, Makarevich PI. Growth factors in regeneration and regenerative medicine: “the cure and the cause”. Front Endocrinol (Lausanne). 2020; 11.

[23] Luo Y, Ye S, Chen X, Gong F, Lu W, Li X. Rush to the fire: FGF21 extinguishes metabolic stress, metaflammation and tissue damage. Cytokine Growth Factor Rev. 2017; 38: 59-65.

[24] House SL, Wang J, Castro AM, Weinheimer C, Kovacs A, Ornitz DM. Fibroblast growth factor 2 is an essential cardioprotective factor in a closed-chest model of cardiac ischemia-reperfusion injury. Physiol Rep. 2015; 3: e12278.

[25] House SL, Castro AM, Lupu TS, Weinheimer C, Smith C, Kovacs A, et al. Endothelial fibroblast growth factor receptor signaling is required for vascular remodeling following cardiac ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2016; 310: H559-71.

[26] Warburton D, Tefft D, Mailleux A, Bellusci S, Thiery JP, Zhao J, et al. Do lung remodeling, repair, and regeneration recapitulate respiratory ontogeny? Am J Respir Crit Care Med. 2001; 164: S59-62.

[27] Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015; 45: 1434-45.

[28] Meyer M, Müller AK, Yang J, Moik D, Ponzio G, Ornitz DM, et al. FGF receptors 1 and 2 are key regulators of keratinocyte migration in vitro and in wounded skin. J Cell Sci. 2012; 125: 5690-701.

[29] Stock A, Kuzis K, Woodward WR, Nishi R, Eckenstein FP. Localization of acidic fibroblast growth factor in specific subcortical neuronal populations. J Neurosci. 1992; 12: 4688-700.

[30] Ye S, Luo Y, Lu W, Jones RB, Linhardt RJ, Capila I, et al. Structural basis for interaction of FGF-1, FGF-2, and FGF-7 with different heparan sulfate motifs. Biochemistry. 2001; 40: 14429-39.

[31] Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell. 2000; 6: 743-50.

[32] Chen G, Liu Y, Goetz R, Fu L, Jayaraman S, Hu MC, et al. α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature. 2018; 553: 461-6.

[33] Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I, et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell. 1997; 89: 693-702.

[34] Wang C, Yang C, Chang JY, You P, Li Y, Jin C, et al. Hepatocyte FRS2α is essential for the endocrine fibroblast growth factor to limit the amplitude of bile acid production induced by prandial activity. Curr Mol Med. 2014; 14: 703-11.

[35] Ornitz DM, Marie PJ. Fibroblast growth factor signaling in skeletal development and disease. Genes Dev. 2015; 29: 1463-86.

[36] Huey DJ, Hu JC, Athanasiou KA. Unlike bone, cartilage regeneration remains elusive. Science. 2012; 338: 917-21.

[37] Liu X, She Y, Wu H, Zhong D, Zhang J. Long non-coding RNA Gas5 regulates proliferation and apoptosis in HCS-2/8 cells and growth plate chondrocytes by controlling FGF1 expression via miR-21 regulation. J Biomed Sci. 2018; 25: 18-8.

[38] Morscheid YP, Venkatesan JK, Schmitt G, Orth P, Zurakowski D, Speicher-Mentges S, et al. rAAV-mediated human FGF-2 gene therapy enhances osteochondral repair in a clinically relevant large animal model over time in vivo. Am J Sports Med. 2021; 49: 958-69.

[39] Saw S, Aiken A, Fang H, McKee T, Bregant S, Sanchez O, et al. Metalloprotease inhibitor TIMP proteins control FGF-2 bioavailability and regulate skeletal growth. J Cell Biol. 2019; 218: 3134-52.

[40] Tang ZF, Li HY. Effects of fibroblast growth factors 2 and low intensity pulsed ultrasound on the repair of knee articular cartilage in rabbits. Eur Rev Med Pharmacol Sci. 2018; 22: 2447-53.

[41] Hung IH, Schoenwolf GC, Lewandoski M, Ornitz DM. A combined series of Fgf9 and Fgf18 mutant alleles identifies unique and redundant roles in skeletal development. Dev Biol. 2016; 411: 72-84.

[42] Le Blanc S, Simann M, Jakob F, Schütze N, Schilling T. Fibroblast growth factors 1 and 2 inhibit adipogenesis of human bone marrow stromal cells in 3D collagen gels. Exp Cell Res. 2015; 338: 136-48.

[43] Hurley MM, Adams DJ, Wang L, Jiang X, Burt PM, Du E, et al. Accelerated fracture healing in transgenic mice overexpressing an anabolic isoform of fibroblast growth factor 2. J Cell Biochem. 2016; 117: 599-611.

[44] Poudel SB, Bhattarai G, Kim JH, Kook SH, Seo YK, Jeon YM, et al. Local delivery of recombinant human FGF7 enhances bone formation in rat mandible defects. J Bone Miner Metab. 2017; 35: 485-96.

[45] Kang MS, Kim JH, Singh RK, Jang JH, Kim HW. Therapeutic-designed electrospun bone scaffolds: mesoporous bioactive nanocarriers in hollow fiber composites to sequentially deliver dual growth factors. Acta Biomater. 2015; 16: 103-16.

[46] Xu J, Huang Z, Wang W, Tan X, Li H, Zhang Y, et al. FGF8 Signaling alters the osteogenic cell fate in the hard palate. J Dent Res. 2018; 97: 589-96.

[47] Wang L, Roth T, Abbott M, Ho L, Wattanachanya L, Nissenson RA. Osteoblast-derived FGF9 regulates skeletal homeostasis. Bone. 2017; 98: 18-25.

[48] Zhou S, Wang Z, Tang J, Li W, Huang J, Xu W, et al. Exogenous fibroblast growth factor 9 attenuates cartilage degradation and aggravates osteophyte formation in post-traumatic osteoarthritis. Osteoarthr Cartil. 2016; 24: 2181-92.

[49] Wei W, Dutchak PA, Wang X, Ding X, Wang X, Bookout AL, et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc Natl Acad Sci U S A. 2012; 109: 3143-8.

[50] Meo Burt P, Xiao L, Hurley MM. FGF23 regulates Wnt/β-catenin Signaling-mediated osteoarthritis in mice overexpressing high-molecular-weight FGF2. Endocrinology. 2018; 159: 2386-96.

[51] Bianchi A, Guibert M, Cailotto F, Gasser A, Presle N, Mainard D, et al. Fibroblast growth factor 23 drives MMP13 expression in human osteoarthritic chondrocytes in a klotho-independent manner. Osteoarthr Cartil. 2016; 24: 1961-9.

[52] Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014; 124: 1587-97.

[53] Guimarães JM, Guimarães ICV, Duarte MEL, Vieira T, Vianna VF, Fernandes MBC, et al. Polymorphisms in BMP4 and FGFR1 genes are associated with fracture non-union. J Orthop Res. 2013; 31: 1971-9.

[54] Jiang Q, Mei L, Zou Y, Ding Q, Cannon RD, Chen H, et al. Genetic polymorphisms in FGFR2 underlie skeletal malocclusion. J Dent Res. 2019; 98: 1340-7.

[55] Xu W, Luo F, Wang Q, Tan Q, Huang J, Zhou S, et al. Inducible activation of FGFR2 in adult mice promotes bone formation after bone marrow ablation. J Bone Miner Res. 2017; 32: 2194-206.

[56] Chen H, Sun X, Yin L, Chen S, Zhu Y, Huang J, et al. PTH 1-34 ameliorates the osteopenia and delayed healing of stabilized tibia fracture in mice with achondroplasia resulting from gain-of-function mutation of FGFR3. Int J Biol Sci. 2017; 13: 1254-65.

[57] Xie Y, Luo F, Xu W, Wang Z, Sun X, Xu M, et al. FGFR3 deficient mice have accelerated fracture repair. Int J Biol Sci. 2017; 13: 1029-37.

[58] Su N, Li X, Tang Y, Yang J, Wen X, Guo J, et al. Deletion of FGFR3 in osteoclast lineage cells results in increased bone mass in mice by inhibiting osteoclastic bone resorption. J Bone Miner Res. 2016; 31: 1676-87.

[59] Xu W, Xie Y, Wang Q, Wang X, Luo F, Zhou S, et al. A novel fibroblast growth factor receptor 1 inhibitor protects against cartilage degradation in a murine model of osteoarthritis. Sci Rep. 2016; 6: 24042.

[60] Tang J, Su N, Zhou S, Xie Y, Huang J, Wen X, et al. Fibroblast growth factor receptor 3 inhibits osteoarthritis progression in the knee joints of adult mice. Arthritis Rheumatol. 2016; 68: 2432-43.

[61] Zhou S, Xie Y, Li W, Huang J, Wang Z, Tang J, et al. Conditional deletion of Fgfr 3 in chondrocytes leads to osteoarthritis-like defects in temporomandibular joint of adult mice. Sci Rep. 2016; 6: 24039.

[62] Kuang L, Wu J, Su N, Qi H, Chen H, Zhou S, et al. FGFR3 deficiency enhances CXCL12-dependent chemotaxis of macrophages via upregulating CXCR7 and aggravates joint destruction in mice. Ann Rheum Dis. 2020; 79: 112-22.

[63] Domingues-Faria C, Vasson MP, Goncalves-Mendes N, Boirie Y, Walrand S. Skeletal muscle regeneration and impact of aging and nutrition. Ageing Res Rev. 2016; 26: 22-36.

[64] Joanisse S, Nederveen JP, Snijders T, McKay BR, Parise G. Skeletal muscle regeneration, repair and remodelling in aging: the importance of muscle stem cells and vascularization. Gerontology. 2016; 63: 91-100.

[65] Pawlikowski B, Vogler TO, Gadek K, Olwin BA-O. Regulation of skeletal muscle stem cells by fibroblast growth factors. Dev Dyn. 2017; 246: 359-67.

[66] Oost LJ, Kustermann M, Armani A, Blaauw B, Romanello V. Fibroblast growth factor 21 controls mitophagy and muscle mass. J Cachexia Sarcopenia Muscle. 2019; 10: 630-42.

[67] Adhikary S, Choudhary D, Tripathi AK, Karvande A, Ahmad N, Kothari P, et al. FGF-2 targets sclerostin in bone and myostatin in skeletal muscle to mitigate the deleterious effects of glucocorticoid on musculoskeletal degradation. Life Sci. 2019; 229: 261-76.

[68] Li J, Han S, Cousin W, Conboy IM. Age-specific functional epigenetic changes in p 21 and p16 in injury-activated satellite cells. Stem cells (Dayton, Ohio). 2015; 33: 951-61.

[69] Benoit B, Meugnier E, Castelli M, Chanon S, Vieille-Marchiset A, Durand C, et al. Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice. Nat Med. 2017; 23: 990-6.

[70] Hankey GJ. Stroke. Lancet. 2017; 389: 641-54.

[71] Campbell BCV, De Silva DA, Macleod MR, Coutts SB, Schwamm LH, Davis SM, et al. Nat Rev Dis Primers. 2019; 5: 70.

[72] Wu F, Chen Z, Tang C, Zhang J, Cheng L, Zuo H, et al. Acid fibroblast growth factor preserves blood-brain barrier integrity by activating the PI3K-Akt-Rac1 pathway and inhibiting RhoA following traumatic brain injury. Am J Transl Res. 2017; 9: 910-25.

[73] Zou Y, Hu J, Huang W, Ye S, Han F, Du J, et al. Non-Mitogenic fibroblast growth factor 1 enhanced angiogenesis following ischemic stroke by regulating the Sphingosine-1-phosphate 1 pathway. Front Pharmacol. 2020; 11: 59.

[74] Nakamura K, Arimura K, Nishimura A, Tachibana M, Yoshikawa Y, Makihara N, et al. Possible involvement of basic FGF in the upregulation of PDGFRβ in pericytes after ischemic stroke. Brain Res. 2016; 1630: 98-108.

[75] Li S, Lu Y, Ding D, Ma Z, Xing X, Hua X, et al. Fibroblast growth factor 2 contributes to the effect of salidroside on dendritic and synaptic plasticity after cerebral ischemia/reperfusion injury. Aaging. 2020; 12: 10951-68.

[76] Zhao YZ, Lin M, Lin Q, Yang W, Yu XC, Tian FR, et al. Intranasal delivery of bFGF with nanoliposomes enhances in vivo neuroprotection and neural injury recovery in a rodent stroke model. J Control Release. 2016; 224: 165-75.

[77] Ye L, Wang X, Cai C, Zeng S, Bai J, Guo K, et al. FGF21 promotes functional recovery after hypoxic-ischemic brain injury in neonatal rats by activating the PI3K/Akt signaling pathway via FGFR1/β-klotho. Exp Neurol. 2019; 317: 34-50.

[78] Wang XM, Xiao H, Liu LL, Cheng D, Li XJ, Si LY. FGF21 represses cerebrovascular aging via improving mitochondrial biogenesis and inhibiting p53 signaling pathway in an AMPK-dependent manner. Exp Cell Res. 2016; 346: 147-56.

[79] Wan H, Yang Y, Li M, Liu X, Sun Y, Wang K, et al. Activation of AK005401 aggravates acute ischemia/reperfusion mediated hippocampal injury by directly targeting YY1/FGF21. Aaging. 2019; 11: 5108-23.

[80] Yang X, Hui Q, Yu B, Huang Z, Zhou P, Wang P, et al. Design and evaluation of lyophilized fibroblast growth factor 21 and its protection against ischemia cerebral injury. Bioconjug Chem. 2018; 29: 287-95.

[81] Wang HW, Jiang X, Zhang Y, Wang J, Xie J, Wang YQ, et al. FGF21 protects against hypoxia injury through inducing HSP72 in cerebral microvascular endothelial cells. Front Pharmacol. 2019; 10: 101.

[82] Wang D, Liu F, Zhu L, Lin P, Han F, Wang X, et al. FGF21 alleviates neuroinflammation following ischemic stroke by modulating the temporal and spatial dynamics of microglia/macrophages. J Neuroinflammation. 2020; 17: 257.

[83] McDonald JW, Sadowsky C. Spinal-cord injury. Lancet. 2002; 359: 417-25.

[84] Witiw CD, Fehlings MG. Acute spinal cord injury. J Spinal Disord Tech. 2015; 28: 202-10.

[85] Chehrehasa F, Cobcroft M, Young YW, Mackay-Sim A, Goss B. An acute growth factor treatment that preserves function after spinal cord contusion injury. J Neurotrauma. 2014; 31: 1807-13.

[86] Xu HL, Tian FR, Lu CT, Xu J, Fan ZL, Yang JJ, et al. Thermo-sensitive hydrogels combined with decellularised matrix deliver bFGF for the functional recovery of rats after a spinal cord injury. Sci Rep. 2016; 6: 38332.

[87] Wang Q, He Y, Zhao Y, Xie HA-O, Lin Q, He Z, et al. A thermosensitive heparin-Poloxamer hydrogel bridges aFGF to treat spinal cord injury. ACS Appl Mater Interfaces. 2017; 9: 6725-45.

[88] Wang Q, Zhang H, Xu H, Zhao Y, Li Z, Li J, et al. Novel multi-drug delivery hydrogel using scar-homing liposomes improves spinal cord injury repair. Theranostics. 2018; 8: 4429-46.

[89] Ye LB, Yu XC, Xia QH, Yang Y, Chen DQ, Wu F, et al. Regulation of Caveolin-1 and Junction Proteins by bFGF Contributes to the Integrity of Blood-Spinal Cord Barrier and Functional Recovery. Neurotherapeutics. 2016; 13: 844-58.

[90] Zhang HY, Zhang X, Wang ZG, Shi HX, Wu FZ, Lin BB, et al. Exogenous basic fibroblast growth factor inhibits ER stress-induced apoptosis and improves recovery from spinal cord injury. CNS Neurosci Ther. 2013; 19: 20-9.

[91] Li J, Wang Q, Wang H, Wu Y, Yin J, Chen J, et al. Lentivirus mediating FGF13 enhances axon regeneration after spinal cord injury by stabilizing microtubule and improving mitochondrial function. J Neurotrauma. 2018; 35: 548-59.

[92] Chen J, Wang Z, Zheng Z, Chen Y, Khor S, Shi K, et al. Neuron and microglia/macrophage-derived FGF10 activate neuronal FGFR2/PI3K/Akt signaling and inhibit microglia/macrophages TLR4/NF-κB-dependent neuroinflammation to improve functional recovery after spinal cord injury. Cell Death Dis. 2017; 8: e3090-0.

[93] Khellaf A, Khan DZ, Helmy A. Recent advances in traumatic brain injury. J Neurol. 2019; 266: 2878-89.

[94] Wang ZG, Cheng Y, Yu XC, Ye LB, Xia QH, Johnson NR, et al. bFGF protects against blood-brain barrier damage through junction protein regulation via PI3K-Akt-Rac1 pathway following traumatic brain injury. Mol Neurobiol. 2016; 53: 7298-311.

[95] Fang X, Ma J, Mu D, Li B, Lian B, Sun C. FGF21 protects dopaminergic neurons in Parkinson’s disease models via repression of Neuroinflammation. Neurotox Res. 2020; 37: 616-27.

[96] Yoshimura S, Teramoto T, Whalen MJ, Irizarry MC, Takagi Y, Qiu J, et al. FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice. J Clin Invest. 2003; 112: 1202-10.

[97] Chen J, Hu J, Liu H, Xiong Y, Zou Y, Huang W, et al. FGF21 protects the blood-brain barrier by upregulating PPARγ via FGFR1/β-klotho after traumatic brain injury. J Neurotrauma. 2018; 35: 2091-103.

[98] Taliyan R, Chandran SK, Kakoty V. Therapeutic approaches to Alzheimer’s type of dementia: a focus on FGF21 mediated neuroprotection. Curr Pharm Des. 2019; 25: 2555-68.

[99] Sun Y, Wang Y, Chen S-T, Chen Y-J, Shen J, Yao W-B, et al. Modulation of the astrocyte-neuron lactate shuttle system contributes to neuroprotective action of fibroblast growth factor 21. Theranostics. 2020; 10: 8430-45.

[100] Niu J, Xie J, Guo K, Zhang X, Xia F, Zhao X, et al. Efficient treatment of Parkinson’s disease using ultrasonography-guided rhFGF20 proteoliposomes. Drug Deliv. 2018; 25: 1560-9.

[101] Yusuf IO, Cheng PH, Chen HM, Chang YF, Chang CY, Yang HI, et al. Fibroblast growth factor 9 suppresses striatal cell death dominantly through ERK Signaling in Huntington’s disease. Cell Physiol Biochem. 2018; 48: 605-17.

[102] Yusuf IO, Chen HM, Cheng PH, Chang CY, Tsai SJ, Chuang JI, et al. Fibroblast growth factor 9 activates anti-oxidative functions of Nrf 2 through ERK signalling in striatal cell models of Huntington’s disease. Free Radic Biol Med. 2019; 130: 256-66.

[103] Sullivan R, Dailey T, Duncan K, Abel N, Borlongan CV. Peripheral nerve injury: stem cell therapy and peripheral nerve transfer. Int J Mol Sci. 2016; 17: 2101.

[104] Li R, Zou S, Wu Y, Li Y, Khor S, Mao Y, et al. Heparin-based coacervate of bFGF facilitates peripheral nerve regeneration by inhibiting endoplasmic reticulum stress following sciatic nerve injury. Oncotarget. 2017; 8: 48086-97.

[105] Li R, Li Y, Wu Y, Zhao Y, Chen H, Yuan Y, et al. Heparin-Poloxamer thermosensitive hydrogel loaded with bFGF and NGF enhances peripheral nerve regeneration in diabetic rats. Biomaterials. 2018; 168: 24-37.

[106] Lee SH, Jin W-P, Seo NR, Pang K-M, Kim B, Kim S-M, et al. Recombinant human fibroblast growth factor-2 promotes nerve regeneration and functional recovery after mental nerve crush injury. Neural Regen Res. 2017; 12: 629-36.

[107] Suzuki Y, Ishikawa N, Tanihara M, Saito S. Nontubulation repair of peripheral nerve gap using heparin/alginate gel combined with b-FGF. Plast Reconstr Surg Glob Open. 2016; 4: e600-0.

[108] Chen B, Hu R, Min Q, Li Y, Parkinson DB, Dun X-P. FGF5 regulates Schwann cell migration and adhesion. Front Cell Neurosci. 2020; 14: 237-7.

[109] Zhu H, Qiao L, Sun Y, Yin L, Huang L, Jiang L, et al. Basic fibroblast growth factor enhances cell proliferation in the dentate gyrus of neonatal rats following hypoxic-ischemic brain damage. Neurosci Lett. 2018; 673: 67-72.

[110] Ye Q, Wu Y, Wu J, Zou S, Al-Zaazaai AA, Zhang H, et al. Neural stem cells expressing bFGF reduce brain damage and restore sensorimotor function after neonatal hypoxia-ischemia. Cell Physiol Biochem. 2018; 45: 108-18.

[111] Çelik Y, Atıcı A, Beydağı H, Reşitoğlu B, Yılmaz N, Ün İ, et al. The effects of fibroblast growth factor-2 and pluripotent astrocytic stem cells on cognitive function in a rat model of neonatal hypoxic-ischemic brain injury. J Matern Fetal Neonatal Med. 2016; 29: 2199-204.

[112] Danopoulos S, Shiosaki J, al Alam D. FGF Signaling in lung development and disease: human versus mouse. Front Genet. 2019; 10: 170-0.

[113] Weinstein M, Xu X, Ohyama K, Deng CX. FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development. 1998; 125: 3615-23.

[114] Tong L, Zhou J, Rong L, Seeley EJ, Pan J, Zhu X, et al. Fibroblast growth Factor-10 (FGF-10) mobilizes lung-resident mesenchymal stem cells and protects against acute lung injury. Sci Rep. 2016; 6: 21642-2.

[115] Wu J, Chu X, Chen C, Bellusci S. Role of fibroblast growth factor 10 in mesenchymal cell differentiation during lung development and disease. Front Genet. 2018; 9: 545-5.

[116] Jones MR, Dilai S, Lingampally A, Chao C-M, Danopoulos S, Carraro G, et al. A comprehensive analysis of fibroblast growth factor receptor 2b Signaling on epithelial tip progenitor cells during early mouse lung branching morphogenesis. Front Genet. 2019; 9: 746-6.

[117] Bellusci S, Grindley J, Emoto H, Itoh N, Hogan BL. Fibroblast growth factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung. Development. 1997; 124: 4867-78.

[118] Prince LS.FGF10 and human lung disease across the life Spectrum. Front Genet. 2018; 9: 517-7.

[119] Yuan T, Volckaert T, Chanda D, Thannickal VJ, De Langhe SP. Fgf10 Signaling in Lung Development, Homeostasis, Disease, and Repair After Injury. Front Genet. 2018; 9: 418. doi: 10.3389/fgene.2018.00418.

[120] Yuan T, Volckaert T, Redente EF, Hopkins S, Klinkhammer K, Wasnick R, et al. FGF10-FGFR2B Signaling generates basal cells and drives alveolar epithelial regeneration by bronchial epithelial stem cells after lung injury. Stem cell reports. 2019; 12: 1041-55.

[121] Liu L, Xia Z, Li J, Hu Y, Wang Q, Chen J, et al. Fibroblast growth factor 10 protects against particulate matter-induced airway inflammatory response through regulating inflammatory signaling and apoptosis. Am J Transl Res. 2019; 11: 6977-88.

[122] Liu L, Song C, Li J, Wang Q, Zhu M, Hu Y, et al. Fibroblast growth factor 10 alleviates particulate matter-induced lung injury by inhibiting the HMGB1-TLR4 pathway. Aging. 2020; 12: 1186-200.

[123] Chen X, Zhao C, Zhang C, Li Q, Chen J, Cheng L, et al. Vagal-α7nAChR signaling promotes lung stem cells regeneration via fibroblast growth factor 10 during lung injury repair. Stem Cell Res Ther. 2020; 11: 230-0.

[124] Scheraga RG, Thompson C, Tulapurkar ME, Nagarsekar AC, Cowan M, Potla R, et al. Activation of heat shock response augments fibroblast growth factor-1 expression in wounded lung epithelium. Am J Physiol Lung Cell Mol Physiol. 2016; 311: L941-55.

[125] Shimbori C, Bellaye PS, Xia J, Gauldie J, Ask KA-OX, Ramos C, et al. Fibroblast growth factor-1 attenuates TGF-β1-induced lung fibrosis. J Pathol. 2016; 240: 197-210.

[126] Koo HY, El-Baz LM, House S, Cilvik SN, Dorry SJ, Shoukry NM, et al. Fibroblast growth factor 2 decreases bleomycin-induced pulmonary fibrosis and inhibits fibroblast collagen production and myofibroblast differentiation. J Pathol. 2018; 246: 54-66.

[127] Guzy RD, Stoilov I, Elton TJ, Mecham RP, Ornitz DM. Fibroblast growth factor 2 is required for epithelial recovery, but not for pulmonary fibrosis, in response to bleomycin. Am J Respir Cell Mol Biol. 2015; 52: 116-28.

[128] Pan X, Xu S, Zhou Z, Wang F, Mao L, Li H, et al. Fibroblast growth factor-2 alleviates the capillary leakage and inflammation in sepsis. Mol Med. 2020; 26: 208.

[129] Tang QY, Wei JX, Xue SF, Liu GH, Fu LX. Fibrogrowth factor-2 protects against acute lung injury by activating the PI3K/Akt signaling pathway. J Biol Regul Homeost Agents. 2020; 34: 1679-88.

[130] Joannes A, Brayer S, Besnard V, Marchal-Sommé J, Jaillet M, Mordant P, et al. FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro. Am J Physiol Lung Cell Mol Physiol. 2016; 310: L615-29.

[131] Humeres C, Frangogiannis NG. Fibroblasts in the infarcted, Remodeling, and failing heart. JACC Basic Transl Sci. 2019; 4: 449-67.

[132] Wang Z, Long DW, Huang Y, Khor S, Li X, Jian X, et al. Fibroblast growth Factor-1 released from a heparin Coacervate improves cardiac function in a mouse myocardial infarction model. ACS Biomater Sci Eng. 2017; 3: 1988-99.

[133] Pascual-Gil S, Simón-Yarza T, Garbayo E, Prósper F, Blanco-Prieto MJ. Cytokine-loaded PLGA and PEG-PLGA microparticles showed similar heart regeneration in a rat myocardial infarction model. Int J Pharm. 2017; 523: 531-3.

[134] Fan C, Tang Y, Zhao M, Lou X, Pretorius D, Menasche P, et al. CHIR99021 and fibroblast growth factor 1 enhance the regenerative potency of human cardiac muscle patch after myocardial infarction in mice. J Mol Cell Cardiol. 2020; 141: 1-10.

[135] Fan C, Oduk Y, Zhao M, Lou X, Tang Y, Pretorius D, et al. Myocardial protection by nanomaterials formulated with CHIR99021 and FGF1. JCI insight. 2020; 5:e132796.

[136] Huang C, Liu Y, Beenken A, Jiang L, Gao X, Huang Z, et al. A novel fibroblast growth factor-1 ligand with reduced heparin binding protects the heart against ischemia-reperfusion injury in the presence of heparin co-administration. Cardiovasc Res. 2017; 113: 1585-602.

[137] Tong G, Liang Y, Xue M, Chen X, Wang J, An N, et al. The protective role of bFGF in myocardial infarction and hypoxia cardiomyocytes by reducing oxidative stress via Nrf 2. Biochem Biophys Res Commun. 2020; 527: 15-21.

[138] Rao Z, Shen D, Chen J, Jin L, Wu X, Chen M, et al. Basic fibroblast growth factor attenuates injury in myocardial infarction by enhancing hypoxia-inducible Factor-1 alpha accumulation. Front Pharmacol. 2020; 11: 1193-3.

[139] Fan C, Shi J, Zhuang Y, Zhang L, Huang L, Yang W, et al. Myocardial-infarction-responsive smart hydrogels targeting matrix metalloproteinase for on-demand growth factor delivery. Adv Mater. 2019; 31: 1902900.

[140] Fan Z, Xu Z, Niu H, Sui Y, Li H, Ma J, et al. Spatiotemporal delivery of basic fibroblast growth factor to directly and simultaneously attenuate cardiac fibrosis and promote cardiac tissue vascularization following myocardial infarction. J Control Release. 2019; 311-312: 233-44.

[141] Wang B, Ma X, Zhao L, Zhou X, Ma Y, Sun H, et al. Injection of basic fibroblast growth factor together with adipose-derived stem cell transplantation: improved cardiac remodeling and function in myocardial infarction. Clin Exp Med. 2016; 16: 539-50.

[142] Nagasawa A, Masumoto HA-O, Yanagi S, Kanemitsu N, Ikeda T, Tabata Y, et al. Basic fibroblast growth factor attenuates left-ventricular remodeling following surgical ventricular restoration in a rat ischemic cardiomyopathy model. Gen Thorac Cardiovasc Surg. 2020; 68: 311-8.

[143] Singla D, Wang J. Fibroblast growth Factor-9 activates c-kit progenitor cells and enhances angiogenesis in the infarcted diabetic heart. Oxidative Med Cell Longev. 2016; 2016: 1-12.

[144] Singla DK, Singla RD, Abdelli LS, Glass C. Fibroblast growth factor-9 enhances M2 macrophage differentiation and attenuates adverse cardiac remodeling in the infarcted diabetic heart. PLoS One. 2015; 10: e0120739-9.

[145] Hu Y, Li L, Shen L, Gao H, Yu F, Yin W, et al. FGF-16 protects against adverse cardiac remodeling in the infarct diabetic heart. Am J Transl Res. 2017; 9: 1630-40.

[146] Wang Z, Huang Y, He Y, Khor S, Zhong X, Xiao J, et al. Myocardial protection by heparin-based coacervate of FGF10. Bioactive materials. 2020; 6: 1867-77.

[147] Yu P, Wilhelm K, Dubrac A, Tung JK, Alves TC, Fang JS, et al. FGF-dependent metabolic control of vascular development. Nature. 2017; 545: 224-8.

[148] Walker KA, Sims-Lucas S, Bates CM. Fibroblast growth factor receptor signaling in kidney and lower urinary tract development. Pediatric nephrology (Berlin, Germany). 2016; 31: 885-95.

[149] Sims-Lucas S, Cusack B, Baust J, Eswarakumar VP, Masatoshi H, Takeuchi A, et al. Fgfr 1 and the IIIc isoform of Fgfr2 play critical roles in the metanephric mesenchyme mediating early inductive events in kidney development. Developmental dynamics: an official publication of the American Association of Anatomists. 2011; 240: 240-9.

[150] Xu Z, Zhu X, Wang M, Lu Y, Dai C. FGF/FGFR2 protects against tubular cell death and acute kidney injury involving Erk1/2 Signaling activation. Kidney Dis. 2020; 6: 181-94.

[151] Pena AM, Chen S, Feng B, Cai L, Li X, Liang G, et al. Prevention of diabetic nephropathy by modified acidic fibroblast growth factor. Nephron. 2017; 137: 221-36.

[152] Tan XH, Zheng XM, Yu LX, He J, Zhu HM, Ge XP, et al. Fibroblast growth factor 2 protects against renal ischaemia/reperfusion injury by attenuating mitochondrial damage and proinflammatory signalling. J Cell Mol Med. 2017; 21: 2909-25.

[153] Qiao J, Uzzo R, Obara-Ishihara T, Degenstein L, Fuchs E, Herzlinger D. FGF-7 modulates ureteric bud growth and nephron number in the developing kidney. Development. 1999; 126: 547-54.

[154] Tan X, Yu L, Yang R, Tao Q, Xiang L, Xiao J, et al. Fibroblast growth factor 10 attenuates renal damage by regulating endoplasmic reticulum stress after ischemia-reperfusion injury. Front Pharmacol. 2020; 11: 39.

[155] Tan X, Zhu H, Tao Q, Guo L, Jiang T, Xu L, et al. FGF10 protects against renal ischemia/reperfusion injury by regulating autophagy and inflammatory Signaling. Front Genet. 2018; 9: 556.

[156] Gao L, Zhong X, Jin J, Li J, Meng XA-OX. Potential targeted therapy and diagnosis based on novel insight into growth factors, receptors, and downstream effectors in acute kidney injury and acute kidney injury-chronic kidney disease progression. Signal Transduct Target Ther. 2020; 5: 9.

[157] Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305: 2432-9.

[158] Al Alam D, Danopoulos S, Schall K, Sala FG, Almohazey D, Fernandez GE, et al. Fibroblast growth factor 10 alters the balance between goblet and Paneth cells in the adult mouse small intestine. Am J Physiol Gastrointest Liver Physiol. 2015; 308: G678-90.

[159] Stark KL, McMahon JA, McMahon AP. FGFR-4, a new member of the fibroblast growth factor receptor family, expressed in the definitive endoderm and skeletal muscle lineages of the mouse. Development. 1991; 113: 641-51.

[160] Vidrich A, Buzan JM, Ilo C, Bradley L, Skaar K, Cohn SM. Fibroblast growth factor receptor-3 is expressed in undifferentiated intestinal epithelial cells during murine crypt morphogenesis. Dev Dyn. 2004; 230: 114-23.

[161] Fu XB, Li X-K, Wang T, Cheng B, Sheng Z-Y. Enhanced anti-apoptosis and gut epithelium protection function of acidic fibroblast growth factor after cancelling of its mitogenic activity. World J Gastroenterol. 2004; 10: 3590-6.

[162] Fu XB, Yang Y-H, Sun T-Z, Chen W, Li J-Y, Sheng Z-Y. Rapid mitogen-activated protein kinase by basic fibroblast growth factor in rat intestine after ischemia/reperfusion injury. World J Gastroenterol. 2004; 9: 1312-7.

[163] Garcia CM, Yu K, Zhao H, Ashery-Padan R, Ornitz DM, Robinson ML, et al. Signaling through FGF receptor-2 is required for lens cell survival and for withdrawal from the cell cycle during lens fiber cell differentiation. Int J Surg. 2011; 96: 467-71.

[164] Song X, Dai D, He X, Zhu S, Yao Y, Gao H, et al. Growth factor FGF2 cooperates with Interleukin-17 to repair intestinal epithelial damage. Immunity. 2015; 43: 488-501.

[165] Egger B, Tolmos J, Procaccino F, Sarosi I, Friess H, Büchler MW, et al. Keratinocyte growth factor promotes healing of left-sided colon anastomoses. Am J Surg. 1998; 176: 18-24.

[166] Cai Y, Wang W, Liang H, Sun L, Teitelbaum DH, Yang H. Keratinocyte growth factor improves epithelial structure and function in a mouse model of intestinal ischemia/reperfusion. PLoS One. 2012; 7: e44772-2.

[167] Yang K, Yin J, Sheng B, Wang Q, Han B, Pu A, et al. AhR-E2F1-KGFR signaling is involved in KGF-induced intestinal epithelial cell proliferation. Mol Med Rep. 2017; 15: 3019-26.

[168] Schall KA, Holoyda KA, Grant CN, Levin DE, Torres ER, Maxwell A, et al. Adult zebrafish intestine resection: a novel model of short bowel syndrome, adaptation, and intestinal stem cell regeneration. Am J Physiol Gastrointest Liver Physiol. 2015; 309: G135-45.

[169] Tai CC, Curtis JL, Sala FG, del Moral PM, Chokshi N, Kanard RJ, et al. Induction of fibroblast growth factor 10 (FGF10) in the ileal crypt epithelium after massive small bowel resection suggests a role for FGF10 in gut adaptation. Dev Dyn. 2009; 238: 294-301.

[170] Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004; 351: 2590-8.

[171] Calmont A, Wandzioch E, Tremblay KD, Minowada G, Kaestner KH, Martin GR, et al. An FGF response pathway that mediates hepatic gene induction in embryonic endoderm cells. Dev Cell. 2006; 11: 339-48.

[172] Berg T, Rountree CB, Lee L, Estrada J, Sala FG, Choe A, et al. Fibroblast growth factor 10 is critical for liver growth during embryogenesis and controls hepatoblast survival via beta-catenin activation. Hepatology (Baltimore, Md). 2007; 46: 1187-97.

[173] Takase HM, Itoh T, Ino S, Wang T, Koji T, Akira S, et al. FGF7 is a functional niche signal required for stimulation of adult liver progenitor cells that support liver regeneration. Genes Dev. 2013; 27: 169-81.

[174] Antoine M, Wirz W, Tag CG, Gressner AM, Marvituna M, Wycislo M, et al. Expression and function of fibroblast growth factor (FGF) 9 in hepatic stellate cells and its role in toxic liver injury. Biochem Biophys Res Commun. 2007; 361: 335-41.

[175] Hanaka H, Hamada T, Ito M, Nakashima H, Tomita K, Seki S, et al. Fibroblast growth factor-5 participates in the progression of hepatic fibrosis. Exp Anim. 2014; 63: 85-92.

[176] Qiu W-H, Zhou B-S, Chu P-G, Chen W-G, Chung C, Shih J, et al. Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World J Gastroenterol. 2005; 11: 5266-72.

[177] French DM, Lin BC, Wang M, Adams C, Shek T, Hötzel K, et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One. 2012; 7: e36713-3.

[178] Harimoto N, Taguchi K, Shirabe K, Adachi E, Sakaguchi Y, Toh Y, et al. The significance of fibroblast growth factor receptor 2 expression in differentiation of hepatocellular carcinoma. Oncology. 2010; 78: 361-8.

[179] Gauglhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, Mohr T, et al. Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology. 2011; 53: 854-64.

[180] Yang H, Fang F, Chang R, Yang L. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology. 2013; 58: 205-17.

[181] Fang F, Chang RM, Yu L, Lei X, Xiao S, Yang H, et al. MicroRNA-188-5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma. J Hepatol. 2015; 63: 874-85.

[182] Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz GD, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol. 2002; 160: 2295-307.

[183] Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005; 2: 217-25.

[184] Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science (New York, NY). 2011; 331: 1621-4.

[185] Schumacher JD, Kong B, Wu J, Rizzolo D, Armstrong LE, Chow MD, et al. Direct and indirect effects of fibroblast growth factor (FGF) 15 and FGF19 on liver fibrosis development. Hepatology (Baltimore, Md). 2020; 71: 670-85.

[186] Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in Ketotic states. Cell Metab. 2007; 5: 426-37.

[187] Adams AC, Yang C, Coskun T, Cheng CC, Gimeno RE, Luo Y, et al. The breadth of FGF21’s metabolic actions are governed by FGFR1 in adipose tissue. Molecular metabolism. 2012; 2: 31-7.

[188] Yang C, Wang C, Ye M, Jin C, He W, Wang F, et al. Control of lipid metabolism by adipocyte FGFR1-mediated adipo-hepatic communication during hepatic stress. Nutr Metab. 2012; 9: 94-4.

[189] Sanyal A, Charles ED, Neuschwander-Tetri BA, Loomba R, Harrison SA, Abdelmalek MF, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet. 2019; 392: 2705-17.

[190] Landén NX, Li D, Ståhle M. Transition from inflammation to proliferation: a critical step during wound healing. Cell Mol Life Sci. 2016; 73: 3861-85.

[191] Hui Q, Jin Z, Li X, Liu C, Wang X. FGF family: from drug development to clinical application. Int J Mol Sci. 2018; 19: 1875.

[192] Wu J, Zhu J, He C, Xiao Z, Ye J, Li Y, et al. Comparative study of heparin-Poloxamer hydrogel modified bFGF and aFGF for in vivo wound healing efficiency. ACS Appl Mater Interfaces. 2016; 8: 18710-21.

[193] Xu HL, Chen PP, Zhu Ge DL, Zhu QY, Jin BH, Shen BX, et al. Liposomes with silk fibroin hydrogel Core to stabilize bFGF and promote the wound healing of mice with deep second-degree scald. Adv Healthc Mater. 2017; 6. https://doi.org/10.1002/adhm.201700344.

[194] Finch PW, Js R, Aaronson SA. Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science. 1989;2454919: 752-5.

[195] Lu W, Luo Y, Kan M, McKeehan WL. Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem. 1999; 274: 12827-34.

[196] Peng C, Chen B, Kao HK, Murphy G, Orgill DP, Guo L. Lack of FGF-7 further delays cutaneous wound healing in diabetic mice. Plast Reconstr Surg. 2011; 128: 673e-84.

[197] Erdag G, Medalie DA, Rakhorst H, Krueger GG, Morgan JR. FGF-7 expression enhances the performance of bioengineered skin. Mol Ther. 2004; 10: 76-85.

[198] Peng Y, Wu S, Tang Q, Li S, Peng C. KGF-1 accelerates wound contraction through the TGF-β1/Smad signaling pathway in a double-paracrine manner. J Biol Chem. 2019; 294: 8361-70.

[199] Yang X, Yang R, Chen M, Zhou Q, Zheng Y, Lu C, et al. KGF-2 and FGF-21 poloxamer 407 hydrogel coordinates inflammation and proliferation homeostasis to enhance wound repair of scalded skin in diabetic rats. BMJ Open Diabetes Res Care. 2020; 8: e001009.

[200] Li W, Yang J, Cai J, Wang H, Tian H, Huang J, et al. Oil body-bound Oleosin-rhFGF-10: a novel drug delivery system that improves skin penetration to accelerate wound healing and hair growth in mice. Int J Mol Sci. 2017; 18: 2177.

[201] Xu K, Chai B, Zhang K, Xiong J, Zhu Y, Xu J, et al. Topical application of fibroblast growth factor 10-PLGA microsphere accelerates wound healing via inhibition of ER stress. Oxidative Med Cell Longev. 2020; 2020: 1-13.

[202] Yen TTH, Thao DTP, Thuoc TL. An overview on keratinocyte growth factor: from the molecular properties to clinical applications. Protein Pept Lett. 2014; 21: 306-17.

[203] Koike Y, Yozaki M, Utani A, Murota H. Fibroblast growth factor 2 accelerates the epithelial-mesenchymal transition in keratinocytes during wound healing process. Sci Rep. 2020; 10: 18545-5.

[204] Wang X, Zhu Y, Sun C, Wang T, Shen Y, Cai W, et al. Feedback activation of basic fibroblast growth factor Signaling via the Wnt/β-catenin pathway in skin fibroblasts. Front Pharmacol. 2017; 8: 32.

[205] Xuan Y, Chi L, Tian H, Cai W, Sun C, Wang T, et al. The activation of the NF-κB-JNK pathway is independent of the PI3K-Rac1-JNK pathway involved in the bFGF-regulated human fibroblast cell migration. J Dermatol Sci. 2016; 82: 28-37.

[206] Liu H, Zhao Y, Zou Y, Huang W, Zhu L, Liu F, et al. Heparin-poloxamer hydrogel-encapsulated rhFGF21 enhances wound healing in diabetic mice. FASEB J. 2019; 33: 9858-70.

[207] Żerańska J, Pasikowska M, Szczepanik B, Mlosek K, Malinowska S, Dębowska RM, et al. A study of the activity and effectiveness of recombinant fibroblast growth factor (Q40P/S47I/H93G rFGF-1) in anti-aging treatment. Postepy dermatologii i alergologii. 2016; 1: 28-36.

[208] Ha JH, Kim HN, Moon KB, Jeon JH, Jung DH, Kim SJ, et al. Recombinant human acidic fibroblast growth factor (aFGF) expressed in Nicotiana benthamiana potentially inhibits skin Photoaging. Planta Med. 2017; 83: 862-9.

[209] Takabayashi Y, Kuwabara M, Sato Y, Ishihara M, Takikawa M, Nakamura S, et al. FGF-2-containing dalteparin/protamine nanoparticles (FGF-2& D/P NPs) ameliorate UV-induced skin photoaging in hairless mice. J Plast Surg Hand Surg. 2018; 52: 375-81.

[210] Kamakura T, Kataoka J, Maeda K, Teramachi H, Mihara H, Miyata K, et al. Platelet-rich plasma with basic fibroblast growth factor for treatment of wrinkles and depressed areas of the skin. Plast Reconstr Surg. 2015; 136: 931-9.

[211] Cvekl A, Zhang X. Signaling and gene regulatory networks in mammalian lens development. Trends in genetics: TIG. 2017; 33: 677-702.

[212] Collins TN, Mao Y, Li H, Bouaziz M, Hong A, Feng G-S, et al. Crk proteins transduce FGF signaling to promote lens fiber cell elongation. elife. 2018; 7: e32586.

[213] Garcia CM, Yu K, Zhao H, Ashery-Padan R, Ornitz DM, Robinson ML, et al. Signaling through FGF receptor-2 is required for lens cell survival and for withdrawal from the cell cycle during lens fiber cell differentiation. Dev Dyn. 2005; 233: 516-27.

[214] Robinson ML, Ohtaka-Maruyama C, Chan CC, Jamieson S, Dickson C, Overbeek PA, et al. Disregulation of ocular morphogenesis by lens-specific expression of FGF-3/int-2 in transgenic mice. Dev Biol. 1998; 198: 13-31.

[215] Carbe C, Zhang X. Lens induction requires attenuation of ERK signaling by Nf1. Hum Mol Genet. 2011; 20: 1315-23.

[216] Kuracha MR, Burgess D, Siefker E, Cooper JT, Licht JD, Robinson ML, et al. Spry1 and Spry2 are necessary for lens vesicle separation and corneal differentiation. Invest Ophthalmol Vis Sci. 2011; 52: 6887-97.

[217] Vega-Meléndez GS, Blagburn JM, Blanco RE. Ciliary neurotrophic factor and fibroblast growth factor increase the speed and number of regenerating axons after optic nerve injury in adult Rana pipiens. J Neurosci Res. 2014; 92: 13-23.

[218] Blanco RE, Vega-Meléndez GS, De La Rosa-Reyes V, Del Cueto C, Blagburn JM. Application of CNTF or FGF-2 increases the number of M2-like macrophages after optic nerve injury in adult Rana pipiens. PLoS One. 2019; 14: e0209733-3.

[219] Zhang J, Cui C, Xu H. Downregulation of miR-145-5p elevates retinal ganglion cell survival to delay diabetic retinopathy progress by targeting FGF5. Biosci Biotechnol Biochem. 2019; 83: 1655-62.

[220] Chen M, Bao L, Zhao M, Cao J, Zheng H. Progress in research on the role of FGF in the formation and treatment of corneal neovascularization. Front Pharmacol. 2020; 11: 111.

[221] Kubo E, Shibata T, Singh DP, Sasaki H. Roles of TGF β and FGF signals in the lens: tropomyosin regulation for posterior capsule opacity. Int J Mol Sci. 2018; 19: 3093.

[222] Eveleth DD, Eveleth JJ, Subramaniam A, Hahn R, Zhou P, Gordon MK, et al. An engineered human fibroblast growth Factor-1 derivative, TTHX1114, ameliorates short-term corneal nitrogen mustard injury in rabbit organ cultures. Invest Ophthalmol Vis Sci. 2018; 59: 4720-30.

[223] Weant J, Eveleth DD, Subramaniam A, Jenkins-Eveleth J, Blaber M, Li L, et al. Regenerative responses of rabbit corneal endothelial cells to stimulation by fibroblast growth factor 1 (FGF1) derivatives, TTHX1001 and TTHX1114. Growth Factors. 2021; 9: 1-14.

[224] Wan J, Goldman D. Opposing actions of Fgf 8a on notch Signaling distinguish two Muller glial cell populations that contribute to retina growth and regeneration. Cell Rep. 2017; 19: 849-62.

[225] Lou ZC, Lou ZH, Xiao J. Regeneration of the tympanic membrane using fibroblast growth factor-2. J Laryngol Otol. 2018; 132: 470-8.

[226] Hakuba N, Tabata Y, Hato N, Fujiwara T, Gyo K. Gelatin hydrogel with basic fibroblast growth factor for tympanic membrane regeneration. Otol Neurotol. 2014; 35: 540-4.

[227] Zhang D, Huang Z, Sun P, Huang H, Zhang Y, Dai J, et al. Acceleration of healing of traumatic tympanic membrane perforation in rats by implanted collagen membrane integrated with collagen-binding basic fibroblast growth factor. Tissue Eng Part A. 2017; 23: 20-9.

[228] Kitamura M, Akamatsu M, Kawanami M, Furuichi Y, Fujii T, Mori M, et al. Randomized placebo-controlled and controlled non-inferiority phase III trials comparing Trafermin, a recombinant human fibroblast growth factor 2, and enamel matrix derivative in periodontal regeneration in Intrabony defects. J Bone Miner Res. 2016; 31: 806-14.

[229] Tanigawa T, Nakayama M, Nakamura T, Inafuku S. Use of trafermin to treat a skin ulcer after repair of a deep auricular laceration: a case report. J Dermatolog Treat. 2005; 16: 345-6.

[230] Yang BB, Gillespie B, Smith B, Smith W, Lissmats A, Rudebeck M, et al. Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin. J Clin Pharmacol. 2015; 55: 1109-18.

[231] Bogousslavsky J, Salinas EO, Pallay A, Donnan GA, Fieschi C, Kaste M, et al. Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc Dis. 2002; 14: 239-51.

[232] Clark WMSJ, Kasner SE, Victor S. Trafermin in acute ischemic stroke. Results of a phase II/III randomized efficacy study. Neurology. 2000; 54: A88.

[233] Lou Z, Wang Y. Evaluation of the optimum time for direct application of fibroblast growth factor to human traumatic tympanic membrane perforations. Growth Factors. 2015; 33: 65-70.

[234] Lou Z, Lou Z, Tang Y, Xiao J. Utility of basic fibroblast growth factor in the repair of blast-induced total or near-total tympanic membrane perforations: a pilot study. Am J Otolaryngol. 2015; 36: 794-7.

[235] Lou Z, Yang J, Tang Y, Xiao J. Risk factors affecting human traumatic tympanic membrane perforation regeneration therapy using fibroblast growth factor-2. Growth Factors. 2015; 33: 410-8.

[236] Lou Z, Huang P, Yang J, Xiao J, Chang J. Direct application of bFGF without edge trimming on human subacute tympanic membrane perforation. Am J Otolaryngol. 2016; 37: 156-61.

[237] Luo Z, Luo Z, Tang Y. Comparative study on the effects of EGF and bFGF on the healing of human large traumatic perforations of the tympanic membrane. Laryngoscope. 2016; 126: E23-8.

[238] Ban M, Lee SC, Park JH, Park KN, Kim HK, Lee SW. Regenerative efficacy of fibroblast growth factor for the treatment of aged vocal fold: from animal model to clinical application. Clin Otolaryngol. 2021; 46: 131-7.

[239] Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, Norgren L, et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet. 2011; 377: 1929-37.

[240] Wu JC, Huang WC, Chen YC, Tu TH, Tsai YA, Huang SF, et al. Acidic fibroblast growth factor for repair of human spinal cord injury: a clinical trial. J Neurosurg Spine. 2011; 15: 216-27.

[241] Lohmander LS, Hellot S, Dreher D, Krantz EFW, Kruger DS, Guermazi A, et al. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014; 66: 1820-31.

[242] Eckstein F, Wirth W, Guermazi A, Maschek S, Aydemir A. Brief report: intraarticular sprifermin not only increases cartilage thickness, but also reduces cartilage loss: location-independent post hoc analysis using magnetic resonance imaging. Arthritis Rheum. 2015; 67: 2916-22.

[243] Hochberg MC, Guermazi A, Guehring H, Aydemir A, Wax S, Fleuranceau-Morel P, et al. Effect of intra-articular sprifermin vs placebo on Femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial. JAMA. 2019; 322: 1360-70.

[244] Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017; 66: 180-90.

[245] Ballinger MD, Shyamala V, Forrest LD, Deuter-Reinhard M, Doyle LV, Wang JX, et al. Semirational design of a potent, artificial agonist of fibroblast growth factor receptors. Nat Biotechnol. 1999; 17: 1199-204.

[246] Fu X, Shen Z, Chen Y, Xie J, Guo Z, Zhang M, et al. Randomised placebo-controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second-degree burns. Lancet. 1998; 352: 1661-4.

[247] Ma B, Cheng DS, Xia ZF, Ben DF, Lu W, Cao ZF, et al. Randomized, multicenter, double-blind, and placebo-controlled trial using topical recombinant human acidic fibroblast growth factor for deep partial-thickness burns and skin graft donor site. Wound Repair Regen. 2007; 15: 795-9.

[248] Abdelhakim M, Lin X, Ogawa R. The Japanese experience with basic fibroblast growth factor in cutaneous wound management and scar prevention: a systematic review of clinical and biological aspects. Dermatol Ther (Heidelb). 2020; 10: 569-87.

[249] Akita S, Akino K, Yakabe A, Tanaka K, Anraku K, Yano H, et al. Basic fibroblast growth factor is beneficial for postoperative color uniformity in split-thickness skin grafting. Wound Repair Regen. 2010; 18: 560-6.

[250] Hayashida K, Akita S. Quality of pediatric second-degree burn wound scars following the application of basic fibroblast growth factor: results of a randomized, controlled pilot study. Ostomy Wound Manage. 2012; 58: 32-6.

[251] Acharya AN, Coates H, Tavora-Vièira D, Rajan GP. A pilot study investigating basic fibroblast growth factor for the repair of chronic tympanic membrane perforations in pediatric patients. Int J Pediatr Otorhinolaryngol. 2015; 79: 332-5.

[252] Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy-and radiotherapy-induced mucositis. Ann Oncol. 2007; 18: 817-26.